Fredun Pharmaceuticals Limited (BOM:539730)

Market Cap	7.33B +114.9%
Revenue (ttm)	5.91B +45.6%
Net Income	326.79M +73.8%
EPS	70.40 +74.5%
Shares Out	4.72M
PE Ratio	22.06
Forward PE	n/a
Dividend	0.70 (0.05%)
Ex-Dividend Date	Sep 23, 2025

Volume	8,204
Average Volume	11,071
Open	1,583.95
Previous Close	1,534.10
Day's Range	1,515.00 - 1,588.95
52-Week Range	635.05 - 1,999.00
Beta	0.56
RSI	39.27
Earnings Date	Feb 9, 2026

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 261
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 539730

Financial Performance

In fiscal year 2025, Fredun Pharmaceuticals's revenue was 4.54 billion, an increase of 30.35% compared to the previous year's 3.48 billion. Earnings were 197.39 million, an increase of 26.34%.